Skip to main content

HDL to Offer BG's Heart Failure Test as Service

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Health Diagnostic Laboratory today said that it has signed an agreement to offer BG Medicine's galectin-3 test as a service to physicians.

The Richmond, Va.-based health management and biomarker-based testing firm, said that it will provide the BG test, which was cleared for marketing by the US Food and Drug Administration in late 2010, to physicians along with its own cardiovascular tests. The test is used as an aid in assessing the prognosis of patients with chronic heart failure.

Financial and other terms of the alliance were not disclosed.

BG's marketing partner, Laboratory Corporation of America, began selling the test in the US in January.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.